AssayIndex
Rollups

Compounds

66 compounds catalogued with hand-authored analytical properties — formula, monoisotopic mass, retention on the index reference method, characteristic impurities and degradation pathways — and the distribution of every result the index holds for each. 63 of them carry at least one record.

66 catalogued63 with records9 classes6,722 reports
CompoundClassMonoisotopic DaRT (min)ReportsBatchesSuppliersMedian %IQR ppSpec %Difficulty
SemaglutideIncretin4111.052418.429261231998.871.0997.01.25
BPC-157Tissue-repair1418.70939.62591941999.151.1298.00.90
TirzepatideIncretin4810.410319.86576962098.441.2397.01.40
RetatrutideIncretin4728.487120.71496741798.411.1296.51.55
TB-500Tissue-repair887.49647.86356671799.470.8298.50.85
IpamorelinGrowth-hormone711.38568.24223411799.480.9799.00.80
PT-141 (Bremelanotide)Melanocortin-receptor1024.52429.52200321599.311.1598.50.90
Melanotan IIMelanocortin-receptor1023.54029.84186271499.240.8998.50.90
GHRP-6Growth-hormone872.44468.44169361799.650.7899.00.85
SemaxNeuroactive813.35417.06160251399.170.9898.50.85
LiraglutideIncretin3748.963117.28154201399.021.0897.51.15
MK-677 (Ibutamoren mesylate)Non-peptide624.218113.86152291699.371.2698.50.80
CJC-1295 (no DAC)Growth-hormone3365.740212.86137311598.611.1698.01.05
CJC-1295 with DACGrowth-hormone3644.974814.62136241398.791.0497.51.20
L-Glutathione (reduced)Short307.08384.28122251599.000.9998.50.90
MOTS-cMetabolic2173.091810.42112211299.181.2698.01.00
SelankNeuroactive751.44026.42112221599.131.1599.00.80
SS-31 (Elamipretide)Metabolic639.38568.9497211299.421.3698.50.85
GHRP-2Growth-hormone817.42759.0697191199.220.6599.00.85
SermorelinGrowth-hormone3355.724512.4296141098.940.8398.01.10
KPVTissue-repair342.22675.2494121099.211.1099.00.75
AOD-9604Metabolic1815.867211.288915799.250.9398.00.95
N-Acetyl Semax AmideNeuroactive854.38067.6289201299.260.9898.50.85
IGF-1 LR3Growth-hormone9105.241216.9286181497.751.0395.01.60
Kisspeptin-10Melanocortin-receptor1301.63009.147013999.271.2898.50.90
SurvodutideIncretin4764.512120.146811998.691.0696.51.45
5-Amino-1MQNon-peptide285.99675.426813999.240.6998.00.85
ARA-290Tissue-repair1189.60968.7265131099.450.8598.00.90
Enclomiphene citrateNon-peptide597.213016.445512999.231.4898.50.90
AfamelanotideMelanocortin-receptor1645.847410.865311699.281.2998.00.95
GonadorelinHypothalamic1181.58258.684910899.280.6498.50.85
NAD+Non-peptide663.10914.164811898.881.0397.01.00
HexarelinGrowth-hormone886.46028.92438798.721.2799.00.85
Humanin (HNG)Metabolic2685.315312.14428799.470.5997.51.05
GHK-CuTissue-repair401.10246.184110998.540.6997.01.20
EpitalonShort390.13874.623711898.631.0299.00.80
ExenatideIncretin4183.937014.92368698.940.9998.01.05
LL-37Tissue-repair4490.426514.36364498.610.9996.51.30
PemvidutideIncretin4679.401420.36355598.410.7896.01.45
PEG-MGFGrowth-hormone7894.000017.24355597.922.1192.01.70
DihexaNeuroactive504.331212.24357699.840.5098.50.85
MazdutideIncretin4912.640819.42336598.110.7096.51.40
PramlintideIncretin3947.106413.94335598.840.6497.51.15
DesmopressinHypothalamic1068.42658.14334499.460.7098.50.95
CagrilintideIncretin3961.321816.74328598.591.2496.51.35
MGFGrowth-hormone2886.511711.62327798.730.6497.51.10
SLU-PP-332Non-peptide410.130015.28323398.690.7298.00.90
L-CarnosineShort226.10663.72295599.071.4199.00.85
IGF-1 DES (1-3)Growth-hormone7365.718815.86285498.531.7095.01.55
LeuprolideHypothalamic1208.66129.44286499.011.0798.50.90
Thymosin α1Tissue-repair3106.549312.72247699.111.0097.51.10
TesamorelinGrowth-hormone5131.927615.44213298.431.7597.01.30
PinealonShort418.18124.86193399.240.7399.00.80
ThymulinTissue-repair873.37166.62183399.060.2798.01.00
AdipotideMetabolic4095.623812.74165498.590.6996.01.35
OxytocinHypothalamic1006.43657.92145599.570.5198.50.95
ThymalinShort——1411n<3—99.01.80
VilonShort275.14813.94111199.150.4099.00.80
GlucagonIncretin3480.619413.61103398.781.2298.01.10
TriptorelinHypothalamic1310.62489.72104498.470.7898.50.90
Follistatin-344Growth-hormone——511n<3—98.01.90
VIPTissue-repair3324.814612.9842298.221.1497.51.15
P21Neuroactive805.397010.4241199.190.3498.00.85
GIP (1-42)Incretin4980.516315.84000n<3—97.01.20
Larazotide acetateTissue-repair749.40727.44000n<3—98.50.85
SetmelanotideMelanocortin-receptor1116.47009.28000n<3—98.01.00
12 compounds

Incretin analogues and co-agonists

GLP-1, GIP and glucagon receptor agonists, including the lipidated long-acting analogues and the dual and triple co-agonists.

Semaglutide

NN9535 · C187H291N45O59

4111.05 DaRT 18.42difficulty 1.25
reports926
median %98.87
spec %97.0

Tirzepatide

LY3298176 · C225H348N48O68

4810.41 DaRT 19.86difficulty 1.40
reports576
median %98.44
spec %97.0

Retatrutide

LY3437943 · C221H342N46O68

4728.49 DaRT 20.71difficulty 1.55
reports496
median %98.41
spec %96.5

Liraglutide

NN2211 · C172H265N43O51

3748.96 DaRT 17.28difficulty 1.15
reports154
median %99.02
spec %97.5

Survodutide

BI 456906 · C220H340N50O67

4764.51 DaRT 20.14difficulty 1.45
reports68
median %98.69
spec %96.5

Exenatide

exendin-4 · C184H282N50O60S

4183.94 DaRT 14.92difficulty 1.05
reports36
median %98.94
spec %98.0

Pemvidutide

ALT-801 · C218H336N48O66

4679.40 DaRT 20.36difficulty 1.45
reports35
median %98.41
spec %96.0

Mazdutide

IBI362 · C226H352N50O70

4912.64 DaRT 19.42difficulty 1.40
reports33
median %98.11
spec %96.5

Pramlintide

AC137 · C171H267N51O53S2

3947.11 DaRT 13.94difficulty 1.15
reports33
median %98.84
spec %97.5

Cagrilintide

AM833 · C194H310N54O61

3961.32 DaRT 16.74difficulty 1.35
reports32
median %98.59
spec %96.5

Glucagon

GCG (1-29) · C153H225N43O49S

3480.62 DaRT 13.61difficulty 1.10
reports10
median %98.78
spec %98.0

GIP (1-42)

glucose-dependent insulinotropic polypeptide · C226H347N57O67S

4980.52 DaRT 15.84difficulty 1.20
reports0
median %—
spec %97.0
08016024092.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=195.50–95.75 %: n=295.75–96.00 %: n=296.00–96.25 %: n=796.25–96.50 %: n=1296.50–96.75 %: n=2196.75–97.00 %: n=3097.00–97.25 %: n=6397.25–97.50 %: n=9797.50–97.75 %: n=15797.75–98.00 %: n=18698.00–98.25 %: n=21598.25–98.50 %: n=22798.50–98.75 %: n=27598.75–99.00 %: n=28399.00–99.25 %: n=27699.25–99.50 %: n=22999.50–99.75 %: n=15299.75–100.00 %: n=164median 98.66 Purity (% area) Reports
Figure. Class-wide purity distribution, 2,399 records across 12 compounds. Median 98.66 % area against a class specification of 97.0 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Metabolic and mitochondrial peptides

Mitochondrial-derived peptides, growth-hormone fragments and peptidomimetics acting on metabolic targets.

MOTS-c

mitochondrial open reading frame of the 12S rRNA type-c · C101H152N28O22S2

2173.09 DaRT 10.42difficulty 1.00
reports112
median %99.18
spec %98.0

SS-31 (Elamipretide)

elamipretide · C32H49N9O5

639.39 DaRT 8.94difficulty 0.85
reports97
median %99.42
spec %98.5

AOD-9604

hGH fragment 176-191 (Tyr-) · C78H123N23O23S2

1815.87 DaRT 11.28difficulty 0.95
reports89
median %99.25
spec %98.0

Humanin (HNG)

HN · C119H182N30O32S

2685.32 DaRT 12.14difficulty 1.05
reports42
median %99.47
spec %97.5

Adipotide

FTPP · C190H332N60O43

4095.62 DaRT 12.74difficulty 1.35
reports16
median %98.59
spec %96.0
024487292.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=497.00–97.25 %: n=497.25–97.50 %: n=497.50–97.75 %: n=997.75–98.00 %: n=1898.00–98.25 %: n=2198.25–98.50 %: n=2198.50–98.75 %: n=2598.75–99.00 %: n=3299.00–99.25 %: n=3699.25–99.50 %: n=4999.50–99.75 %: n=5099.75–100.00 %: n=83median 99.26 Purity (% area) Reports
Figure. Class-wide purity distribution, 356 records across 5 compounds. Median 99.26 % area against a class specification of 98.0 %. Same fixed 92–100 % domain as every other purity histogram here.
10 compounds

Tissue-repair and immunomodulatory peptides

Short to medium linear peptides marketed for tissue repair, mucosal integrity and immune modulation.

BPC-157

Body Protection Compound 157 · C62H98N16O22

1418.71 DaRT 9.62difficulty 0.90
reports591
median %99.15
spec %98.0

TB-500

thymosin β4 fragment (17-23) · C39H69N9O14

887.50 DaRT 7.86difficulty 0.85
reports356
median %99.47
spec %98.5

KPV

Lys-Pro-Val · C16H30N4O4

342.23 DaRT 5.24difficulty 0.75
reports94
median %99.21
spec %99.0

ARA-290

cibinetide · C50H83N15O18

1189.61 DaRT 8.72difficulty 0.90
reports65
median %99.45
spec %98.0

GHK-Cu

copper tripeptide-1 · C14H22CuN6O4

401.10 DaRT 6.18difficulty 1.20
reports41
median %98.54
spec %97.0

LL-37

human cathelicidin LL-37 · C205H340N60O53

4490.43 DaRT 14.36difficulty 1.30
reports36
median %98.61
spec %96.5

Thymosin α1

Tα1 · C129H215N33O55

3106.55 DaRT 12.72difficulty 1.10
reports24
median %99.11
spec %97.5

Thymulin

serum thymic factor · C35H55N9O17

873.37 DaRT 6.62difficulty 1.00
reports18
median %99.06
spec %98.0

VIP

vasoactive intestinal peptide · C147H238N44O42S

3324.81 DaRT 12.98difficulty 1.15
reports4
median %98.22
spec %97.5

Larazotide acetate

AT-1001 · C34H55N9O10

749.41 DaRT 7.44difficulty 0.85
reports0
median %—
spec %98.5
08416825292.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=196.75–97.00 %: n=297.00–97.25 %: n=197.25–97.50 %: n=1297.50–97.75 %: n=1897.75–98.00 %: n=4598.00–98.25 %: n=6198.25–98.50 %: n=10098.50–98.75 %: n=10298.75–99.00 %: n=14099.00–99.25 %: n=12499.25–99.50 %: n=16399.50–99.75 %: n=16299.75–100.00 %: n=298median 99.26 Purity (% area) Reports
Figure. Class-wide purity distribution, 1,229 records across 10 compounds. Median 99.26 % area against a class specification of 98.0 %. Same fixed 92–100 % domain as every other purity histogram here.
13 compounds

Growth-hormone axis peptides

GHRH analogues, growth-hormone secretagogues, IGF-1 variants and conjugates.

Ipamorelin

NNC 26-0161 · C38H49N9O5

711.39 DaRT 8.24difficulty 0.80
reports223
median %99.48
spec %99.0

GHRP-6

growth hormone releasing hexapeptide · C46H56N12O6

872.44 DaRT 8.44difficulty 0.85
reports169
median %99.65
spec %99.0

CJC-1295 (no DAC)

mod-GRF (1-29) · C152H252N44O42

3365.74 DaRT 12.86difficulty 1.05
reports137
median %98.61
spec %98.0

CJC-1295 with DAC

CJC-1295 DAC · C165H269N47O46

3644.97 DaRT 14.62difficulty 1.20
reports136
median %98.79
spec %97.5

GHRP-2

pralmorelin · C45H55N9O6

817.43 DaRT 9.06difficulty 0.85
reports97
median %99.22
spec %99.0

Sermorelin

GRF (1-29) · C149H246N44O42

3355.72 DaRT 12.42difficulty 1.10
reports96
median %98.94
spec %98.0

IGF-1 LR3

Long R3 IGF-1 · C400H625N111O116S9

9105.24 DaRT 16.92difficulty 1.60
reports86
median %97.75
spec %95.0

Hexarelin

examorelin · C47H58N12O6

886.46 DaRT 8.92difficulty 0.85
reports43
median %98.72
spec %99.0

PEG-MGF

pegylated mechano growth factor · conjugate (24-mer + 5 kDa mPEG)

7894.00 DaRT 17.24difficulty 1.70
reports35
median %97.92
spec %92.0

MGF

mechano growth factor · C121H200N42O37

2886.51 DaRT 11.62difficulty 1.10
reports32
median %98.73
spec %97.5

IGF-1 DES (1-3)

DES(1-3)IGF-1 · C317H508N92O95S7

7365.72 DaRT 15.86difficulty 1.55
reports28
median %98.53
spec %95.0

Tesamorelin

TH9507 · C221H366N72O67S

5131.93 DaRT 15.44difficulty 1.30
reports21
median %98.43
spec %97.0

Follistatin-344

FS-344 · recombinant protein (344 aa)

mass not defineddifficulty 1.90
reports5
median %—
spec %98.0
06112218392.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=495.75–96.00 %: n=496.00–96.25 %: n=696.25–96.50 %: n=196.50–96.75 %: n=996.75–97.00 %: n=1297.00–97.25 %: n=1597.25–97.50 %: n=2297.50–97.75 %: n=3597.75–98.00 %: n=5498.00–98.25 %: n=9098.25–98.50 %: n=10198.50–98.75 %: n=8798.75–99.00 %: n=11099.00–99.25 %: n=12199.25–99.50 %: n=10899.50–99.75 %: n=10999.75–100.00 %: n=215median 99.00 Purity (% area) Reports
Figure. Class-wide purity distribution, 1,103 records across 13 compounds. Median 99.00 % area against a class specification of 98.0 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Melanocortin-receptor peptides

Cyclic and linear melanocortin agonists, plus the kisspeptin decapeptide.

PT-141 (Bremelanotide)

bremelanotide · C50H68N14O10

1024.52 DaRT 9.52difficulty 0.90
reports200
median %99.31
spec %98.5

Melanotan II

MT-II · C50H69N15O9

1023.54 DaRT 9.84difficulty 0.90
reports186
median %99.24
spec %98.5

Kisspeptin-10

KP-10 · C63H83N17O14

1301.63 DaRT 9.14difficulty 0.90
reports70
median %99.27
spec %98.5

Afamelanotide

NDP-α-MSH · C78H111N21O19

1645.85 DaRT 10.86difficulty 0.95
reports53
median %99.28
spec %98.0

Setmelanotide

RM-493 · C49H68N18O9S2

1116.47 DaRT 9.28difficulty 1.00
reports0
median %—
spec %98.0
0397811792.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=197.00–97.25 %: n=197.25–97.50 %: n=197.50–97.75 %: n=897.75–98.00 %: n=1598.00–98.25 %: n=2698.25–98.50 %: n=4598.50–98.75 %: n=4298.75–99.00 %: n=3599.00–99.25 %: n=7199.25–99.50 %: n=6699.50–99.75 %: n=6199.75–100.00 %: n=137median 99.28 Purity (% area) Reports
Figure. Class-wide purity distribution, 509 records across 5 compounds. Median 99.28 % area against a class specification of 98.5 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Hypothalamic and posterior-pituitary hormones

GnRH analogues and the nonapeptide hormones, several of which have pharmacopoeial monographs.

Gonadorelin

GnRH · C55H75N17O13

1181.58 DaRT 8.68difficulty 0.85
reports49
median %99.28
spec %98.5

Desmopressin

DDAVP · C46H64N14O12S2

1068.43 DaRT 8.14difficulty 0.95
reports33
median %99.46
spec %98.5

Leuprolide

leuprorelin · C59H84N16O12

1208.66 DaRT 9.44difficulty 0.90
reports28
median %99.01
spec %98.5

Oxytocin

Pitocin · C43H66N12O12S2

1006.44 DaRT 7.92difficulty 0.95
reports14
median %99.57
spec %98.5

Triptorelin

D-Trp6-LHRH · C64H82N18O13

1310.62 DaRT 9.72difficulty 0.90
reports10
median %98.47
spec %98.5
09182792.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=197.50–97.75 %: n=197.75–98.00 %: n=298.00–98.25 %: n=398.25–98.50 %: n=1798.50–98.75 %: n=1398.75–99.00 %: n=1199.00–99.25 %: n=1699.25–99.50 %: n=2399.50–99.75 %: n=1699.75–100.00 %: n=31median 99.30 Purity (% area) Reports
Figure. Class-wide purity distribution, 134 records across 5 compounds. Median 99.30 % area against a class specification of 98.5 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Neuroactive and cognitive peptides

ACTH-derived and tuftsin-derived peptides, lipidated tripeptide amides and adamantylated fragments.

Semax

Met-Glu-His-Phe-Pro-Gly-Pro · C37H51N9O10S

813.35 DaRT 7.06difficulty 0.85
reports160
median %99.17
spec %98.5

Selank

TP-7 · C33H57N11O9

751.44 DaRT 6.42difficulty 0.80
reports112
median %99.13
spec %99.0

N-Acetyl Semax Amide

NASA · C39H54N10O10S

854.38 DaRT 7.62difficulty 0.85
reports89
median %99.26
spec %98.5

Dihexa

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · C27H44N4O5

504.33 DaRT 12.24difficulty 0.85
reports35
median %99.84
spec %98.5

P21

P021 · C36H55N9O12

805.40 DaRT 10.42difficulty 0.85
reports4
median %99.19
spec %98.0
029588792.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=497.50–97.75 %: n=597.75–98.00 %: n=1398.00–98.25 %: n=1698.25–98.50 %: n=2798.50–98.75 %: n=3698.75–99.00 %: n=4699.00–99.25 %: n=5399.25–99.50 %: n=5099.50–99.75 %: n=4999.75–100.00 %: n=101median 99.25 Purity (% area) Reports
Figure. Class-wide purity distribution, 400 records across 5 compounds. Median 99.25 % area against a class specification of 98.5 %. Same fixed 92–100 % domain as every other purity histogram here.
6 compounds

Short bioregulator peptides

Di-, tri- and tetrapeptide bioregulators, plus the thiol tripeptide glutathione and the dipeptide carnosine.

Epitalon

epithalon · C14H22N4O9

390.14 DaRT 4.62difficulty 0.80
reports37
median %98.63
spec %99.0

L-Carnosine

β-alanyl-L-histidine · C9H14N4O3

226.11 DaRT 3.72difficulty 0.85
reports29
median %99.07
spec %99.0

Pinealon

Glu-Asp-Arg · C15H26N6O8

418.18 DaRT 4.86difficulty 0.80
reports19
median %99.24
spec %99.0

Thymalin

thymus polypeptide extract · polypeptide mixture

mass not defineddifficulty 1.80
reports14
median %—
spec %99.0

Vilon

Lys-Glu · C11H21N3O5

275.15 DaRT 3.94difficulty 0.80
reports11
median %99.15
spec %99.0
012243692.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=196.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=597.50–97.75 %: n=1097.75–98.00 %: n=398.00–98.25 %: n=2098.25–98.50 %: n=1398.50–98.75 %: n=2398.75–99.00 %: n=2599.00–99.25 %: n=3599.25–99.50 %: n=2099.50–99.75 %: n=2299.75–100.00 %: n=41median 99.06 Purity (% area) Reports
Figure. Class-wide purity distribution, 218 records across 6 compounds. Median 99.06 % area against a class specification of 99.0 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Non-peptide adjuncts

Small molecules and nucleotide cofactors submitted alongside peptides. Different specification, different methods, same index.

5-Amino-1MQ

5-amino-1-methylquinolinium · C10H11N2+ · I−

286.00 DaRT 5.42difficulty 0.85
reports68
median %99.24
spec %98.0

Enclomiphene citrate

enclomiphene · C26H28ClNO · C6H8O7

597.21 DaRT 16.44difficulty 0.90
reports55
median %99.23
spec %98.5

NAD+

nicotinamide adenine dinucleotide · C21H27N7O14P2

663.11 DaRT 4.16difficulty 1.00
reports48
median %98.88
spec %97.0

SLU-PP-332

ERR pan-agonist SLU-PP-332 · C22H22N2O4S

410.13 DaRT 15.28difficulty 0.90
reports32
median %98.69
spec %98.0
021426392.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=197.25–97.50 %: n=497.50–97.75 %: n=1097.75–98.00 %: n=1998.00–98.25 %: n=2398.25–98.50 %: n=3098.50–98.75 %: n=3598.75–99.00 %: n=3099.00–99.25 %: n=4399.25–99.50 %: n=4499.50–99.75 %: n=4399.75–100.00 %: n=73median 99.17 Purity (% area) Reports
Figure. Class-wide purity distribution, 355 records across 5 compounds. Median 99.17 % area against a class specification of 98.5 %. Same fixed 92–100 % domain as every other purity histogram here.